Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, both at the molecular
and histological level. High-throughput sequencing and gene expression profiling have …

Background and Aims Activation of the antitumor immune response using programmed
death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with …

Background & aims Agents that induce an immune response against tumors by altering T-
cell regulation have increased survival times of patients with advanced-stage tumors, such …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Immune cells constitute an important element of tumor tissue. Accumulating evidence
indicates their clinicopathological significance in predicting prognosis and therapeutic …